Overexpression of PDL-1 is a risk factor for lymph node metastasis in cervical cancer
Keywords:
cervical cancer, metastasis, PDL-1, risk factorAbstract
Cervical cancer is the fourth most prevalent malignancy in women globally and and the 2nd in Indonesia. In 2008, the Indonesian Cancer Foundation projected that 52 million Indonesian women are at risk for cervical cancer, and that 36% of all cancer patients are cervical cancer patients. Increasing by 0.6% per year. There are 9,496 cervical cancer-related deaths in Indonesia, compared to an estimated 24,400 worldwide. The crude incidence rate of cervical cancer in Indonesia is 17 per 100.000 women. The majority of individuals with cervical cancer who passed away have received chemotherapy and radiation therapy. In recent years, tremendous progress has been made in immune therapy studies focused at preventing cancers from evading the immune response of the tumor. Among them is PD-I research. The association between PD-1 and its PDL-1 ligand suppresses cytotoxic T cells in the immune response to tumors. PDL-1 overexpression was also associated with a poor prognosis in a few other carcinomas. This study intends to determine whether PDL I overexpression is a risk factor for cervical cell carcinoma metastasis. Metastasis is indicative of a poor prognosis in cancer.
Downloads
References
Azuma, K., Ota, K., Kawahara, A., Hattori, S., Iwama, E., Harada, T., ... & Okamoto, I. (2014). Association of PD-L1 overexpression with activating EGFR mutations in surgically resected nonsmall-cell lung cancer. Annals of oncology, 25(10), 1935-1940. https://doi.org/10.1093/annonc/mdu242
Berman, M. L., Keys, H., Creasman, W., DiSaia, P., Bundy, B., & Blessing, J. (1984). Survival and patterns of recurrence in cervical cancer metastatic to periaortic lymph nodes: a gynecologic oncology group study. Gynecologic oncology, 19(1), 8-16. https://doi.org/10.1016/0090-8258(84)90151-3
Biewenga, P., Buist, M. R., Moerland, P. D., van Themaat, E. V. L., van Kampen, A. H., ten Kate, F. J., & Baas, F. (2008). Gene expression in early stage cervical cancer. Gynecologic oncology, 108(3), 520-526. https://doi.org/10.1016/j.ygyno.2007.11.024
Bilgin, B., Sendur, M. A., Bülent Ak?nc?, M., ?ener Dede, D., & Yalç?n, B. (2017). Targeting the PD-1 pathway: a new hope for gastrointestinal cancers. Current Medical Research and Opinion, 33(4), 749-759.
Bruni, L., Barrionuevo-Rosas, L., Albero, G., Serrano, B., Mena, M., Gómez, D., ... & De Sanjosé, S. (2017). ICO information centre on HPV and cancer (HPV information centre). Human papillomavirus and related diseases in the world. Summary Report, 27.
Buskwofie, A., David-West, G., & Clare, C. A. (2020). A review of cervical cancer: incidence and disparities. Journal of the National Medical Association, 112(2), 229-232. https://doi.org/10.1016/j.jnma.2020.03.002
Droeser, R. A., Hirt, C., Viehl, C. T., Frey, D. M., Nebiker, C., Huber, X., ... & Tornillo, L. (2013). Clinical impact of programmed cell death ligand 1 expression in colorectal cancer. European journal of cancer, 49(9), 2233-2242. https://doi.org/10.1016/j.ejca.2013.02.015
Endo, D., Todo, Y., Okamoto, K., Minobe, S., Kato, H., & Nishiyama, N. (2015). Prognostic factors for patients with cervical cancer treated with concurrent chemoradiotherapy: a retrospective analysis in a Japanese cohort. Journal of gynecologic oncology, 26(1), 12-18.
Erdogdu, I. H. (2019). MHC class 1 and PDL-1 status of primary tumor and lymph node metastatic tumor tissue in gastric cancers. Gastroenterology research and practice, 2019.
Eto, S., Yoshikawa, K., Nishi, M., Higashijima, J., Tokunaga, T., Nakao, T., ... & Shimada, M. (2016). Programmed cell death protein 1 expression is an independent prognostic factor in gastric cancer after curative resection. Gastric cancer, 19, 466-471.
Ferlay, J., Colombet, M., Soerjomataram, I., Parkin, D. M., Piñeros, M., Znaor, A., & Bray, F. (2021). Cancer statistics for the year 2020: An overview. International journal of cancer, 149(4), 778-789.
Ferns, D. M., Heeren, A. M., Samuels, S., Bleeker, M. C., de Gruijl, T. D., Kenter, G. G., & Jordanova, E. S. (2016). Classical and non-classical HLA class I aberrations in primary cervical squamous-and adenocarcinomas and paired lymph node metastases. Journal for immunotherapy of cancer, 4(1), 1-11.
Goncalves, A., Fabbro, M., Lhomme, C., Gladieff, L., Extra, J. M., Floquet, A., ... & Viens, P. (2008). A phase II trial to evaluate gefitinib as second-or third-line treatment in patients with recurring locoregionally advanced or metastatic cervical cancer. Gynecologic oncology, 108(1), 42-46. https://doi.org/10.1016/j.ygyno.2007.07.057
Haie-Meder, C., Morice, P., & Castiglione, M. (2010). Cervical cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Annals of Oncology, 21, v37-v40.
Hodi, F. S., O'day, S. J., McDermott, D. F., Weber, R. W., Sosman, J. A., Haanen, J. B., ... & Urba, W. J. (2010). Improved survival with ipilimumab in patients with metastatic melanoma. New England Journal of Medicine, 363(8), 711-723.
Huang, B., Cai, J., Xu, X., Guo, S., & Wang, Z. (2016). High-grade tumor budding stratifies early-stage cervical cancer with recurrence risk. PloS one, 11(11), e0166311.
Kumar, V., Abbas, A. K., Fausto, N., & Aster, J. C. (2014). Robbins and Cotran pathologic basis of disease, professional edition e-book. Elsevier health sciences.
Kurman , RJ , Ronnett , BM , Sherman , ME , & Wilkinson , EJ (2010). Tumors of the Cervix, Vagina, and Vulva AFIP Atlas of Tumor Pathology, Fourth Series, Facicle 13. Washington, DC: Armed Forces Instituteof Pathology .
Liu, Y., Wu, L., Tong, R., Yang, F., Yin, L., Li, M., ... & Lu, Y. (2019). PD-1/PD-L1 inhibitors in cervical cancer. Frontiers in Pharmacology, 10, 65.
Lorusso, D., Petrelli, F., Coinu, A., Raspagliesi, F., & Barni, S. (2014). A systematic review comparing cisplatin and carboplatin plus paclitaxel-based chemotherapy for recurrent or metastatic cervical cancer. Gynecologic oncology, 133(1), 117-123. https://doi.org/10.1016/j.ygyno.2014.01.042
Massard, C., Gordon, M. S., Sharma, S., Rafii, S., Wainberg, Z. A., Luke, J., ... & Segal, N. H. (2016). Safety and efficacy of durvalumab (MEDI4736), an anti–programmed cell death ligand-1 immune checkpoint inhibitor, in patients with advanced urothelial bladder cancer. Journal of Clinical Oncology, 34(26), 3119.
Mezache, L., Paniccia, B., Nyinawabera, A., & Nuovo, G. J. (2015). Enhanced expression of PD L1 in cervical intraepithelial neoplasia and cervical cancers. Modern Pathology, 28(12), 1594-1602.
Mustika, I. W., Candra, I. W., & SC, N. Y. (2017). The Relationship between the Level of Spiritual and Self-Esteem on Depression towards Patients with Diabetes Mellitus. International Research Journal of Engineering, IT and Scientific Research, 2(7), 125-133.
Pamela Kusumadewi Putri Thaib, P., & Anny Setijo Rahaju, A. (2021). Clinicopathological profile of clear cell renal cell carcinoma. International journal of health & medical sciences, 5(1), 91-100.
Peters, P., Bandi, H., Efendy, J., Perez-Smith, A., & Olson, S. (2010). Rapid growth of cervical cancer metastasis in the brain. Journal of Clinical Neuroscience, 17(9), 1211-1212. https://doi.org/10.1016/j.jocn.2010.01.021
Sahasrabudhe, N. M., Van der Horst, J. C., Spaans, V., Kenter, G., De Kroon, C., Bosse, T., ... & Jordanova, E. S. (2019). MGL ligand expression is correlated to lower survival and distant metastasis in cervical squamous cell and adenosquamous carcinoma. Frontiers in Oncology, 9, 29.
Šmahel, M. (2017). PD-1/PD-L1 blockade therapy for tumors with downregulated MHC class I expression. International journal of molecular sciences, 18(6), 1331.
Strauss, L., Mahmoud, M. A., Weaver, J. D., Tijaro-Ovalle, N. M., Christofides, A., Wang, Q., ... & Boussiotis, V. A. (2020). Targeted deletion of PD-1 in myeloid cells induces antitumor immunity. Science immunology, 5(43), eaay1863.
Waggoner, S. E. (2003). Cervical cancer. The lancet, 361(9376), 2217-2225. https://doi.org/10.1016/S0140-6736(03)13778-6
Wherry, E. J., & Kurachi, M. (2015). Molecular and cellular insights into T cell exhaustion. Nature Reviews Immunology, 15(8), 486-499.
Wu, C., Zhu, Y., Jiang, J., Zhao, J., Zhang, X. G., & Xu, N. (2006). Immunohistochemical localization of programmed death-1 ligand-1 (PD-L1) in gastric carcinoma and its clinical significance. Acta histochemica, 108(1), 19-24. https://doi.org/10.1016/j.acthis.2006.01.003
Yokoyama, S., Miyoshi, H., Nishi, T., Hashiguchi, T., Mitsuoka, M., Takamori, S., ... & Ohshima, K. (2016). Clinicopathologic and prognostic implications of programmed death ligand 1 expression in thymoma. The Annals of thoracic surgery, 101(4), 1361-1369.
Zerdes, I., Matikas, A., Bergh, J., Rassidakis, G. Z., & Foukakis, T. (2018). Genetic, transcriptional and post-translational regulation of the programmed death protein ligand 1 in cancer: biology and clinical correlations. Oncogene, 37(34), 4639-4661.
Published
How to Cite
Issue
Section
Copyright (c) 2023 International journal of health & medical sciences
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
Articles published in the International Journal of Health & Medical Sciences (IJHMS) are available under Creative Commons Attribution Non-Commercial No Derivatives Licence (CC BY-NC-ND 4.0). Authors retain copyright in their work and grant IJHMS right of first publication under CC BY-NC-ND 4.0. Users have the right to read, download, copy, distribute, print, search, or link to the full texts of articles in this journal, and to use them for any other lawful purpose.
Articles published in IJHMS can be copied, communicated and shared in their published form for non-commercial purposes provided full attribution is given to the author and the journal. Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgment of its initial publication in this journal.
